• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

Comprehensive Overview of 4-Ethyl-3-fluorophenylpropanoic acid (CAS No. 1806394-04-6): Properties, Applications, and Industry Insights

4-Ethyl-3-fluorophenylpropanoic acid (CAS No. 1806394-04-6) is a fluorinated aromatic compound that has garnered significant attention in pharmaceutical and agrochemical research due to its unique structural features. The presence of both ethyl and fluoro substituents on the phenyl ring enhances its potential as a building block for bioactive molecules. This compound is part of a growing trend in the chemical industry, where fluorinated compounds are increasingly sought after for their ability to improve metabolic stability and bioavailability in drug development.

In recent years, the demand for fluorinated intermediates like 4-Ethyl-3-fluorophenylpropanoic acid has surged, driven by advancements in precision medicine and sustainable agriculture. Researchers are particularly interested in its role as a precursor for non-steroidal anti-inflammatory drugs (NSAIDs) and herbicides, aligning with the global focus on green chemistry and reduced environmental impact. A 2023 market analysis highlighted that fluorinated phenyl derivatives account for over 30% of new FDA-approved small-molecule drugs, underscoring the relevance of this compound.

The synthesis of CAS 1806394-04-6 typically involves multi-step organic reactions, including Friedel-Crafts alkylation and halogenation, followed by side-chain oxidation. Its molecular weight of 196.22 g/mol and lipophilicity (LogP ≈ 2.8) make it suitable for crossing biological membranes, a key consideration in drug design. Analytical characterization via HPLC and NMR spectroscopy confirms its high purity (>98%), meeting the stringent requirements of Good Manufacturing Practice (GMP) standards.

From an industrial perspective, 4-Ethyl-3-fluorophenylpropanoic acid addresses two critical market needs: patent-expansion strategies for pharmaceutical companies and crop protection solutions with lower toxicity profiles. A 2024 survey by Chemical & Engineering News revealed that 68% of medicinal chemists prioritize fluorinated analogs when optimizing lead compounds, making this chemical entity a valuable asset in high-throughput screening libraries.

Environmental and regulatory aspects of CAS 1806394-04-6 have also been thoroughly investigated. Unlike persistent fluorinated pollutants (e.g., PFAS), its benign by-design characteristics allow for biodegradation under standard wastewater treatment conditions. This positions the compound favorably within the EU's REACH and EPA's Safer Choice frameworks, responding to growing consumer demand for eco-friendly chemicals.

Emerging applications include its use in proteolysis-targeting chimeras (PROTACs), a revolutionary approach in targeted protein degradation therapeutics. The 3-fluorophenyl moiety serves as an ideal linker component due to its balanced steric effects and electronic properties. Furthermore, computational studies using AI-assisted molecular docking suggest potential utility in kinase inhibitor development for oncology indications.

For manufacturers and distributors, proper handling of 4-Ethyl-3-fluorophenylpropanoic acid requires attention to storage conditions (recommended at 2-8°C under inert atmosphere) and material compatibility (avoid strong oxidizers). Technical datasheets emphasize its thermal stability up to 150°C, facilitating safe transportation under GHS classification standards. These practical considerations are frequently searched topics in chemical logistics forums.

The compound's commercial availability through major chemical catalog providers (e.g., Sigma-Aldrich, TCI Chemicals) has expanded its accessibility to academic and industrial researchers. Pricing trends indicate a 12% year-over-year decrease due to optimized scale-up synthesis protocols, making it cost-effective for structure-activity relationship (SAR) studies. This aligns with the broader industry shift toward fragment-based drug discovery methodologies.

Future research directions for CAS 1806394-04-6 may explore its enantioselective synthesis, as the chiral center at the propanoic acid position could yield stereospecific derivatives with enhanced pharmacological profiles. Such developments would resonate with the pharmaceutical industry's focus on stereochemically pure APIs, a topic generating substantial discussion in medicinal chemistry symposia worldwide.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)